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Abstract
Earlier studies have shown that psoriasis in Japan and Thailand is associated with
two different major histocompatibility complex (MHC) haplotypes – those bearing
HLA-Cw6 and those bearing HLA-Cw1 and HLA-B46. In an independent case-
control sample from Thailand, we confirmed the association of psoriasis with both
haplotypes. No association was seen in Thai HLA-Cw1 haplotypes lacking HLA-B46,
nor was HLA-Cw1 associated with psoriasis in a large Caucasian sample. To assess
whether these risk haplotypes share a common origin, we sequenced genomic DNA
from a Thai HLA-Cw1-B46 homozygote across the ∼300 kb MHC risk interval, and
compared it with sequence of a HLA-Cw6-B57 risk haplotype. Three small regions of
homology were found, but these regions share equivalent sequence similarity with one
or more clearly non-risk haplotypes, and they contain no polymorphism alleles unique
to all risk haplotypes. Differences in psoriasis phenotype were also observed, including
lower risk of disease, greater nail involvement, and later age at onset in HLA-Cw1-B46
carriers compared with HLA-Cw6 carriers. These findings suggest locus heterogeneity
at PSORS1 (psoriasis susceptibility 1), the major psoriasis susceptibility locus in the
MHC, with HLA-Cw6 imparting risk in both Caucasians and Asians, and an allele
other than HLA-Cw1 on the HLA-Cw1-B46 haplotype acting as an additional risk
variant in East Asians.
Introduction
Human leukocyte antigen (HLA) associations with psoriasis
have been known for nearly 40 years (1). Earlier studies
localized the disease determinant to the class I end of the
MHC (2, 3) and assigned the name PSORS1 [OMIM (Online
Mendelian Inheritance in Man) # 177900] to this locus (4).
Association with HLA-Cw6 is particularly strong in many
different world populations (5), and recent sequencing and
haplotype analyses of Caucasian and Chinese Han psoriatics
have indicated that HLA-Cw6 itself is likely to be the
susceptibility determinant on these chromosomes, rather than
any of 10 nearby genes in the 300-kb PSORS1 candidate
interval (6, 7). The prevalence of psoriasis differs markedly
throughout the world (8). While it is unclear whether genetic
or environmental factors are primarily responsible for this
variation, it has been suggested that the rarity of psoriasis
in Australian aborigines and several Amerindian populations
is correlated with the absence of HLA haplotypes carrying
HLA-Cw6 (8).
Several studies have documented a strong association
between psoriasis and another HLA haplotype that is com-
mon in Japan and Thailand, but extremely rare in Caucasians
(HLA-A*0207, -B*4601, -Cw*01 ) (9–13). This haplotype was
associated with psoriasis when found in cis to any of three
HLA class II haplotypes (10), suggesting that the disease
determinant resides on the class I end of these haplotypes.
Interestingly, all studies but one (9) found that the HLA-Cw1-
B46 haplotype imparts considerably lower risk for psoriasis
than does HLA-Cw6. There is also some evidence that this
determinant produces a different clinical form of psoriasis as
HLA-Cw1-B46 is equally associated with early or late-onset
disease (9, 10), whereas HLA-Cw6 is much more strongly
associated with early-onset psoriasis in both Thais (10) and
Caucasians (14).
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A major goal of this study was to determine whether the
HLA-Cw1-B46 psoriasis risk haplotype found in Japanese (12,
13, 15) and Thai (9, 10) populations and the HLA-Cw6 -
bearing psoriasis risk haplotypes found in both Caucasians
and Asians represent allelic or locus heterogeneity at the
PSORS1 locus, or if they share a disease locus inherited iden-
tical by descent (IBD) from a common ancestor. To this end,
we cloned and sequenced the PSORS1 candidate interval of
the HLA-Cw1-B46 haplotype for comparison with sequences
for the HLA-Cw6-B57 and HLA-Cw6-B50 risk haplotypes and
nine non-risk MHC haplotypes that were derived by us (6) and
the Sanger Centre (16). In addition, we looked for differences
in associated relative risk and phenotype of the HLA-Cw1-B46
and HLA-Cw6 -bearing haplotypes in a previously unreported
sample of 206 Thai cases and 114 Thai controls. Finally, we
compared the haplotype compositions and odds ratios (ORs)
for association of HLA-Cw1 in our Caucasian and Thai sam-
ples. Together, these analyses confirm that HLA-Cw1-B46 is
a psoriasis risk haplotype in the Thai population, demonstrate
that HLA-Cw1 is unlikely to be a direct determinant of risk for
psoriasis in the Caucasian or Thai populations, and strongly
suggest that the disease determinants carried on these two
ancestral haplotypes are not derived from a common ancestor.
Materials and methods
Subjects
Informed consent was obtained from all subjects under
protocols adherent to the Declaration of Helsinki principles
and approved by the Institutional Review Boards of the
participating institutions. In the Caucasian sample, which
consisted of 2438 cases and 2311 controls, most affected
individuals were identified through the dermatology services
of the University of Michigan Medical Center, the Ann Arbor
Veterans Affairs Medical Center, and Henry Ford Hospital of
Detroit. A few psoriatics were also provided by the National
Psoriasis Foundation Tissue Bank. Individuals were defined as
affected if chronic plaque or guttate psoriasis lesions covered
more than 1% of the total body surface area (TBSA) or if
at least two skin, scalp, nail or joint lesions were clinically
diagnostic of psoriasis (17). Controls were recruited from the
southeast Michigan area, and were required to be unrelated
to each other or to any case, and to be free of a family
history of psoriasis. For this study, only cases and controls
of self-reported European Caucasian origin were analyzed.
The Thai sample consisted of 206 psoriasis cases and 114
normal controls, all collected at the Institute of Dermatology
in Bangkok, Thailand, using the same inclusion and exclusion
criteria used for the Caucasian sample.
DNA preparation
Genomic DNA was prepared from heparinized whole blood
using previously established methods (18). Blood samples
collected in Bangkok were transported to Ann Arbor for DNA
preparation within 4 days.
Genotyping
Eight single-nucleotide polymorphisms (SNPs) in exons 2
and 3 of the HLA-C gene were genotyped – rs1131151,
rs28732105, rs1050409, rs1131123, rs1131118, rs1050384,
rs17839985, and rs41547419 at positions 89, 213, 218, 341,
361, 387, 459, and 540 of the coding sequence. These
SNPs allow absolute discrimination of HLA-C to a trial-
lelic level (Cw1 /Cw6 /neither), even in the absence of exter-
nal phasing information, for all known alleles in release
2.10.00 of the IMGT-HLA Sequence Database (19); URL:
http://www.ebi.ac.uk/imgt/hla). Six SNPs in exons 2 and
3 of the HLA-B gene were also genotyped – rs713031 ,
rs41562914, rs1131204, rs41553715, rs1071652, and rs2308
466 at positions 142, 206, 277, 299, 362, and 560 of the
coding sequence. These SNPs provide typing of HLA-B to a
biallelic level (B46 /other) in the absence of phasing informa-
tion for all known alleles in release 2.16.00 of the IMGT-HLA
database. All SNPs were typed by single-base primer exten-
sion, as implemented in the SnapShot assay protocol (Applied
Biosystems, Foster City, CA), per the manufacturer’s instruc-
tions. Polymerase chain reaction (PCR) amplification and
SnapShot extension primer sequences are provided in Table
S1 (Supporting Information). Microsatellites were genotyped
by PCR amplification using fluorescently labeled forward
and unlabeled reverse primers followed by size determina-
tion by capillary electrophoresis on an Applied Biosystems
3100 Genetic Analyzer.
Cloning and sequencing
A Thai psoriatic who was homozygous for the HLA-Cw1-B46
haplotype throughout the 300-kb PSORS1 candidate region
(31.129–31.429 Mb on build 36.3 of the human reference
sequence for chromosome 6) was identified by genotyping
HLA-C, HLA-B, and 10 microsatellite markers extending from
MICA to telomeric of CDSN. A fosmid library was prepared
from the genomic DNA of this individual and screened for
the region of interest, as previously described (6). Thirteen
overlapping fosmid clones that provided complete coverage
of the risk interval were selected, with no attempt made
to distinguish clones from the maternal or paternal chro-
mosome. Inserts of each fosmid clone were subjected to
shotgun sequencing, as described previously (6). High qual-
ity sequence coverage from at least two different plasmid
subclones – and from both strands, whenever possible – was
required for the entire fosmid insert, which resulted in a
22-fold average depth of coverage. The published sequence
of the HLA-Cw7-B8 haplotype of the Cox homozygous cell
line (20) was used as both a reference for sequence alignment
and for the numbering of the coordinate system used in the
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tables and figures of the present study, which starts at the first
base of the 5′ primer (GCAACTTTTCTGTCAATCCA) used
to amplify microsatellite marker D6S273 and extends in the
telomeric direction. Overlapping fosmid clone sequences were
assembled into a single contig; the resulting 337.1 kb of HLA-
Cw1-B46 haplotype sequence (spanning 31.105–31.446 Mb
on human reference) has been deposited in Genbank (acces-
sion number GQ472773).
Association analysis
Single marker association was evaluated using a chi-squared
contingency test of allelic counts; asymptotic P-values are
reported. Haplotype inference and haplotype-based asso-
ciation tests were carried out with v1.07 of PLINK (21);
http://pngu.mgh.harvard.edu/purcell/plink. For standard hap-
lotype association, a logistic regression model with an allele
dosage term was used, and P-values were determined with
1 million permutations of case-control status. For condi-
tional haplotype-based association, a test of whether HLA-
Cw1 has effects independent of HLA-B46 was constructed
as a likelihood ratio test comparing an alternative model
with separate effects for each of the three HLA-Cw1-B46
haplotypes to a null model which groups the Cw1+/B46−
and Cw1−/B46− haplotypes together. An analagous con-
ditional test for independent effect of HLA-B46 compares
association of the Cw1+/B46+ and Cw1+/B46− haplotypes.
Meta-analysis of disease associations in the two Thai studies
used Cochran-Mantel-Haenszel test procedures. Power calcu-
lations were carried out with version 3.1 of G*POWER (22);
http://www.psycho.uni-duesseldorf.de/aap/projects/gpower.
Sequence analysis
The HLA-Cw1-B46 sequence was aligned with the other
18 MHC haplotype sequences using SeqMan (DNASTAR, ver-
sion 8.0.2); whenever necessary, sequence alignments were
manually adjusted to yield the minimum possible num-
ber of polymorphisms. For each polymorphism, its location
in the Cox HLA-Cw7-B8 reference sequence and its alle-
les for all 19 haplotypes were recorded. MHC haplotype
sequences were then compared with that of the HLA-Cw6-
B57 haplotype by determining the percentage difference of
polymorphic alleles over 2.5-kb intervals. Regions of similar-
ity between pairs of MHC haplotype sequences were delin-
eated by a two-step approach (23). Rough bounds were first
obtained using a moving window of 2.5 kb with a lag of
100 bp and a criterion of at least 80% identity of alleles
for all included polymorphisms. Recursive entropic segmen-
tation (24) with a stopping criterion based on the Bayesian
information criterion (25) was then applied as a second-
stage refinement. Version 0.97-600-1000 of the MINCOV pro-
gram (26); (http://www.stanford.edu/group/molepi/free softw
are.html) was used to search for minimal combinations
of polymorphism alleles unique to risk haplotypes. MHC
haplotype sequences within regions of homology were clus-
tered using an average-distance agglomerative hierarchical
method with a metric of percentage difference of polymor-
phism alleles. Multiple instances of a single MHC haplotype
(viz., two HLA-Cw6-B57, two Cw7-B7, two Cw8-B65, three
Cw7-B8, two Cw3-B62, and two Cw12-B38 haplotypes) were
consolidated into a single representative consensus sequence
before comparison of sequence similarity and combinatorial
analysis. All 19 available MHC sequences were used for
clustering.
Phenotype analysis
Five phenotypic aspects of psoriasis were measured at entry
into the study: age at onset of disease, TBSA involvement
of lesions, toenail involvement, fingernail involvement, and
arthritis. All traits were compared for four different HLA-CB
phenotypes (carriage of HLA-Cw1-B46 but no HLA-Cw6, car-
riage of HLA-Cw6 but no HLA-Cw1-B46, carriage of both
HLA-Cw6 and HLA-Cw1-B46, carriage of neither HLA-Cw1-
B46 nor HLA-Cw6 ), as well as all six possible HLA-CB
genotypes involving these two alleles. Age at onset and TBSA
were analyzed by one-way analysis of variance (ANOVA) after
transforming the variables to approximate normality with the
optimal Box–Cox power transformation (power of 0.8 for age
at onset and 0.3 for TBSA); P-values were determined using
10,000 randomizations of the response variable observations.
There were no significant departures from the assumption of
homogeneity of variances for either of the transformed vari-
ables, as assessed by a randomization version of Levine’s
test. Sheffe’s modified S-method (27, 28) was used for an
unplanned comparison of mean age at onset of HLA-Cw6 car-
riers vs noncarriers; it controls the experimentwise error rate
at the nominal level for all possible linear contrasts of the
group means. Nail involvement and arthritis were analyzed by
unordered two-way contingency tables, using Fisher’s exact
test to determine the significance of association between phe-
notype variables and HLA-C status. Standardized Pearson
residuals were examined to determine the relative contribu-
tions of different cells of the contingency table to the overall
test result, and a 2 × 2 contingency table was used to analyze
nail involvement for HLA-Cw1-B46 carriers vs noncarriers.
Results
Association analysis
As shown in Table 1, in our Thai sample, HLA-Cw6, HLA-
Cw1 and HLA-B46 all are significantly associated with
psoriasis (P = 3.2 × 10−6, 0.0011 and 0.0017, respectively).
The associations with HLA-Cw1 and HLA-B46 are driven
entirely by association with an underlying HLA-Cw1-B46
haplotype (P = 0.0016, Table 2). In this sample HLA-B46 is
invariably linked with HLA-Cw1 (i.e. no HLA-Cw1−/B46+
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Table 1 Single marker analysis of HLA-Cw1, HLA-Cw6, and HLA-B46 associations with psoriasis in Thais and Caucasians
Thais Caucasians
Frequency (proportion) in Frequency (proportion) in
Allele Cases Controls OR (95% CI)a Pb Cases Controls OR (95% CI)a Pb




(0.2338) (0.1238) (1.35, 3.46) (0.0330) (0.0394) (0.67, 1.03)
HLA-Cw6 71 9 4.79
3.2 × 10−6 1139 420 3.05 1.3 × 10−78
(0.1766) (0.0429) (2.34, 9.80) (0.2336) (.0909) (2.70, 3.44)




(0.1955) (0.0991) (1.33, 3.66) (0.0000) (0.0000)
aOdds ratio and its 95% confidence interval for the allelic association test.
bP-value for allelic association test; multiallelic P-value for HLA-C is 3.4 × 10−8 in Thais and 3.2 × 10−77 in Caucasians.
cFrequency of HLA-B46 in Caucasians is based on typing all HLA-Cw1-positive individuals (160 cases and 174 controls successfully typed) and a large
subsample of HLA-Cw1-negative individuals (505 cases and 667 controls successfully typed).






controls OR (95% CI)a Pb
+ + 0.1965 0.0991 2.25 (1.34, 3.80) 0.0016
+ − 0.0373 0.0283 1.34 (0.51, 3.57) 0.63
− + 0.0000 0.0000 — —
− − 0.7662 0.8726 0.46 (0.28, 0.75) 0.0012
aOdds ratio and its 95% confidence interval in logistic regression dosage
model for association.
bGlobal P-value = 0.0036; all the P-values based on 1 million permuta-
tions.
haplotypes); however, HLA-Cw1 haplotypes lacking HLA-
B46 do occur at a low frequency of ∼3%, but they show a
much smaller effect size (OR = 1.34) and are not significantly
associated with psoriasis (P = 0.63). Similarly, conditional
haplotype-based association testing found no evidence that
HLA-Cw1 is associated independently of HLA-B46 (P =
0.33), or vice versa (P = 0.52).
Although HLA-Cw6 appears to be more strongly associ-
ated with psoriasis than HLA-Cw1-B46 (OR = 4.79 vs 2.16),
the difference in ORs is not significant as their 95% con-
fidence intervals (CI) overlap. Because of increased power,
a meta-analysis that combines the allelic counts in our Thai
sample with those of a previous Thai study (10) is able to
show a significantly greater association of psoriasis with HLA-
Cw6 (OR = 5.10, 95% CI = 3.23–8.06, P = 2.1 × 10−14)
than with HLA-Cw1-B46 (OR = 2.16, 95% CI = 1.61–2.88,
P = 1.4 × 10−7). The other Asian studies (9, 11–13) used
serological typing, so their results could not be easily com-
bined with the more recent allele-based studies, but it is note-
worthy that three of four of these older studies also show a
greater strength of association for HLA-Cw6.
We also looked for HLA-C associations in a Caucasian
sample of 2438 cases and 2311 controls (Table 1). While
HLA-Cw6 was very strongly associated with psoriasis in
this sample (OR = 3.05, P = 1.3 × 10−78), HLA-Cw1 was
clearly unassociated (OR = 0.83, P = 0.097). Despite the
lower allele frequency of HLA-Cw1 in the Caucasian cohort
(3.9% in Caucasian controls versus 12.4% in the Thai
controls), our large sample had essentially 100% power to
detect association if it indeed exists, assuming a multiplicative
model, a significance level α = 0.05, and an OR of 2.16
(similar to that in Thais); our sample had 80% power to
detect an association with an OR as low as 1.32. HLA-B46
did not occur in our Caucasian sample, neither among all 334
HLA-Cw1 -positive individuals nor among a large typed subset
of 1172 HLA-Cw1 -negative individuals (95% CI for HLA-
B46 frequency = 0.0000–0.0026 in 730 randomly selected
controls and 0.0000–0.0035 in 545 randomly selected cases).
Sequence comparisons
In order to determine the DNA sequence of the PSORS1
risk region on the HLA-Cw1-B46 haplotype, an affected Thai
individual homozygous for this haplotype was identified by
HLA typing and microsatellite genotyping, and a fosmid
library was prepared and screened as described in Meth-
ods. A total of 13 overlapping fosmid clones were isolated
that provided complete coverage of a 337 kb region extend-
ing from 15 kb telomeric of HLA-B to 90 kb centromeric of
CDSN. The sequenced interval fully includes a 298-kb candi-
date region for PSORS1 shared by all known HLA-Cw6 risk
haplotypes (6). We then compared this sequence to a collec-
tion of genomic DNA sequences generated by ourselves (6)
and by the MHC Haplotype Project (16). Besides providing
new examples of haplotypes we previously sequenced (HLA-
Cw7-B8, Cw7-B7, Cw3-B62, and Cw6-B57 ), inclusion of the
MHC Haplotype Project sequences contributed sequences for
four new haplotypes (HLA-Cw5-B18, Cw5-B44, Cw16-B44,
and Cw3-B60 ) that all appear to be non-risk from our pre-
vious analysis (6). All together, 19 sequences were available,
including those for 11 distinct MHC haplotypes that were
complete enough for sequence comparison in the candidate
interval.
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Figure 1 Sequence comparison of 10 MHC class I haplotypes with the HLA-Cw6-B57 risk haplotype. Known genes and their direction of transcription,
as well as a 9.7-kb indel are shown above the coordinate axis. Genes expressing non-coding RNA are colored cyan, and those expressing protein are
colored red. Three delineations of the PSORS1 candidate region (6) are shown below the coordinate axis. The per cent disagreement of polymorphism
alleles, when compared with the HLA-Cw6-B57 haplotype, is plotted for each haplotype using a moving 2.5-kb window with a 500-bp lag. The bottom
panel plots the number of polymorphisms that are variable among all sequenced haplotypes; only these polymorphisms were considered when
computing per cent disagreement. Regions of sequence homology at least 5 kb in length between the HLA-Cw1-B46 and HLA-Cw6-B57 haplotypes
are mapped as five-numbered orange bars in the top panel; these bars are also shown on all other haplotypes sharing the same regions of homology.
As shown in Figure 1, the HLA-Cw1-B46 and HLA-Cw6-
B57 haplotypes exhibit substantial allelic divergence for more
than three-quarters of the sequenced interval. Nevertheless,
within the 331 kb region encompassing most sequences, four
of 7364 qualifying polymorphisms carry an allele common to
all three psoriasis risk haplotypes (HLA-Cw6-B57, Cw6-B50,
and Cw1-B46 ) that is not found on any of the eight non-
risk haplotypes (Table 3). Furthermore, there are more than
59,000 two-way combinations and 2 billion three-way combi-
nations of polymorphism alleles fulfilling this same criterion
for a potential IBD disease locus. Progressively narrowing
the region of comparison to each of three different PSORS1
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No. of combinations of polymorphisms









indels 1-way 2-way 3-way
1 343.0–351.3 8.3 11 218 214 4.1 3.7 0 0 0
2 452.1–507.6 55.5 10 915 881 4.5 4.0 0 31 13,272
3 536.8–597.1 12.8 11 92 91 12.0 11.0 0 0 0
4 585.1–597.1 12.0 10 159 158 5.0 5.1 0 0 0
5 677.9–683.1 5.2 11 34 33 11.8 12.1 0 0 0
158 kb 359.9–517.1 157.6 10 4983 4912 46.9 46.7 4 13,817 3.8 × 107
224 kb 359.9–583.4 223.6 9 5673 5571 46.1 45.7 4 17,421 5.4 × 107
298 kb 359.9–657.6 297.7 9 6608 6470 46.5 46.0 4 38,109 1.8 × 108
Entire 343.0–673.8 330.8 9 7364 7211 44.7 44.1 4 59,555 2.5 × 109
aRegion of MHC sequence as shown in Figure 1; ‘entire’ refers to the full interval for which most MHC haplotypes were sequenced.
bNumber of different haplotype sequences being compared that are fully sequenced for the region; this number varies among regions because three
of the Sanger Centre sequences have gaps in coverage.
cNumber of polymorphisms that are variable for sequences being compared; separate tallies are given for all types of polymorphisms and for SNPs
and indels only (i.e. excluding STRs and poly-A/T variations, which tend to have higher mutation rates).
dPer cent disagreement of polymorphism alleles between the HLA-Cw1-B46 and HLA-Cw6-B57 risk haplotypes.
eNumber of one-way, two-way, and three-way allelic combinations of polymorphisms that are both common and unique to the three psoriasis risk
haplotypes (Cw1-B46, Cw6-B57, and Cw6-B50) when compared with all non-risk haplotypes.
candidate regions (298, 224, and 158 kb), which were delin-
eated by previous work (6), only modestly reduces the number
of potential disease loci (Table 3). However, if HLA-Cw6 and
HLA-Cw1-B46 risk haplotypes are indeed descended from
a common PSORS1 -bearing ancestor, then the disease locus
should occur within a region of sequence homology. Five such
regions at least 5 kb in length, marked in orange in Figure 1,
could be delineated. Two of these (regions 1 and 5) occur out-
side the 298-kb candidate interval that is the shortest region
common to all known HLA-Cw6 risk haplotypes, and two of
the remaining three (regions 3 and 4) are unpromising can-
didates for an IBD disease region as these short (12.8 and
12.0 kb, respectively) intervals bear no polymorphism alleles
or combinations of alleles unique to the risk haplotypes. Fur-
thermore, region 4 falls ouside of a 224-kb PSORS1 candidate
interval firmly established by ancestral recombinant haplotype
analysis, and region 3 falls outside of a probable although not
definitively established 158-kb candidate interval.
The final and largest region of homology, region 2, is a
55.5-kb interval between HLA-C and HCG27 with 95.5%
allelic identity at all 915 variable polymorphisms and a
96.0% allelic identity among the 881 more stable SNPs and
indels [i.e. excluding highly mutable poly-A/T and short
tandem repeat (STR) variations]. Region 2 bears no single
polymorphism with an allele restricted to risk haplotypes, but
it does have 31 two-way and 13,272 three-way combinations
of polymorphism alleles unique to risk. However, as can be
seen in Figure 1, the three risk haplotypes share roughly
equivalent levels of sequence similarity in region 2 with
two clearly non-risk haplotypes (HLA-Cw7-B8 and Cw8-
B65 ). This visual comparison is confirmed more rigorously
by the clustering dendograms of Figure 2. For region 2,
the clustering distance separating the non-risk HLA-Cw7-
B8 haplotypes from any of the HLA-Cw6 risk haplotypes
is substantially less than the distance between the HLA-
Cw6 and HLA-Cw1-B46 risk haplotypes, and the former
distance is actually slightly less than that between the two
different HLA-Cw6 haplotypes, which are almost certainly
IBD in this region. Furthermore, the non-risk HLA-Cw8-B65
haplotype is only slightly more different from HLA-Cw1-B46
in region 2 than is the latter haplotype from the HLA-Cw6
haplotypes. Figure 2 shows a similar situation for regions 3
and 4. Extended regions of sequence similarity where only
a few common haplotypes are observed (haplotype blocks)
are commonplace within the MHC (29) and elsewhere in
the human genome (30), which makes it difficult to test for
identity by descent among these risk haplotypes. The lack of
any known expressed genes or single polymorphism alleles
unique to risk in region 2 argues strongly against an IBD
disease locus in this interval, but a risk-specific haplotype of
an unknown gene or of an intergenic regulatory element within
the 55 kb defined by region 2 could conceivably be common
to all three risk haplotypes, as long as it spans at least 2.3 kb
(the minimum interval encompassed by any of the two-way
or three-way allelic combinations unique to risk haplotypes).
Phenotype comparisons
We next undertook a comparison of psoriasis phenotype of
Thais carrying HLA-Cw1-B46 vs HLA-Cw6, under the hypoth-
esis that if the two HLA risk haplotypes share a common
causative variant, then the resulting disease phenotype should
392 © 2010 John Wiley & Sons A/S · Tissue Antigens 76, 387–397
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Figure 2 Sequence variation among MHC class I haplotypes within
three regions of homology between HLA-Cw1-B46 and HLA-Cw6-B57.
Hierarchical clustering dendrograms are shown. HLA-Cw6 haplotypes
are shown in red, and the HLA-Cw1-B46 haplotype in cyan. The
clustering distance metric is per cent disagreement of polymorphism
alleles within the region.
be similar in the same genetic population. As shown in
Table 4, among the four HLA-CB phenotypes significant dif-
ferences were observed for mean age at onset, toenail involve-
ment, and fingernail involvement (P = 0.043, 0.0048, and
0.0070, respectively). No significant differences in TBSA
involvement or arthritis were observed (P = 0.098 and 0.84,
respectively).
Inspection of group means in Table 4 shows that age at
onset is about 6 years earlier in the two groups of HLA-Cw6
carriers (30.0 and 30.2 years) than for either the HLA-Cw1-
B46 only carriers (36.9 years) or carriers of neither risk hap-
lotype (35.3 years). The contrast of the average of the mean
transformed age at onset for the two groups of HLA-Cw6
carriers compared with the average of the mean transformed
onset for the two groups of HLA-Cw6 noncarriers is sig-
nificant (P = 0.037). Conversely, inspection of standardized
Pearson residuals for the four HLA-CB phenotype groups
indicates that greater nail involvement for the two groups of
HLA-Cw1-B46 carriers (36.4% and 26.3% for toenail, 36.4%
and 31.6% for fingernail) vs lesser involvement for either
HLA-Cw6 only carriers (10.2% and 14.3% for toenail and
fingernail) or carriers of neither risk haplotype (15.4% and
14.1% for toenail and fingernail) is largely responsible for
the significant test findings of the 4 × 2 contingency table.
Collapsing the contingency table to a 2 × 2 format based
on HLA-Cw1-B46 carriage yields a strong positive associ-
ation for both toenail involvement (OR = 3.30, P = 0.0010)
and fingernail involvement (OR = 3.28, P = 0.00074). TBSA
trends higher in HLA-Cw6 carriers (34.2% vs 25.5%), and
the marginal lack of significance for variation among groups
may be because of inadequate power of our Thai sample, as
increased TBSA has been shown to be associated with HLA-
Cw6 in Caucasians (31). The findings for arthritis have little
meaning given the low incidence of this trait (1.5%) among
Thai affecteds in the sample.
Differences of disease phenotype among HLA-CB geno-
types were similar to those seen among HLA-CB phenotypes,
with mean age at onset lower in all groups carrying one or
more copies of HLA-Cw6, and toenail and fingernail involve-
ment higher in all groups carrying one or more copies of HLA-
Cw1-B46 (data not shown). However, only the differences
in toenail and fingernail involvement were significant (P =
0.018 and 0.024, respectively). The weaker significances for
HLA-CB genotype compared with HLA-CB phenotype may be
a simple outcome of subdividing a relatively small sample into
six vs four categories with a concomitant reduction in power.
Discussion
Genome-wide linkage scans (17, 32) as well as more recent
genome-wide association studies (33–36) have made it clear
that the major genetic determinant of psoriasis resides within
the MHC. We have identified HLA-Cw6 as the predominant
PSORS1 disease allele in the Caucasian population (6), and
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involvement (mean ± SE)
Per cent fingernail
involvement (mean ± SE)
Per cent arthritis
(mean ± SE)
Cw1-B46 only 55 36.9 ± 1.6 26.2 ± 2.4 36.4 ± 6.5 36.4 ± 6.5 1.8 ± 1.8
Cw6 only 49 30.0 ± 2.3 34.2 ± 3.6 10.2 ± 4.3 14.3 ± 5.0 0.0 ± 0.0
Cw6 + Cw1-B46 19 30.2 ± 3.2 34.2 ± 6.3 26.3 ± 10.1 31.6 ± 10.7 0.0 ± 0.0
Neither 78 35.3 ± 1.8 24.7 ± 2.1 15.4 ± 4.1 14.1 ± 3.9 2.6 ± 1.8
Missing 5 34.8 ± 8.3 28.2 ± 8.9 40.0 ± 21.9 40.0 ± 21.9 0.0 ± 0.0
Total 206 34.0 ± 1.1 28.3 ± 1.5 21.4 ± 2.9 22.3 ± 2.9 1.5 ± 0.8
Pd 0.043 0.098 0.0048 0.0070 0.84
aHLA-CB phenotype is based on the carriage of HLA-CB haplotypes by the individual, where HLA-C is typed to a Cw1/Cw6/neither level and HLA-B
to a B46/other level; i.e. ‘Cw1-B46 only’ designates individuals with one or two copies of a HLA-Cw1-B46 haplotype but no copies of a HLA-Cw6
haplotype, ‘Cw6 only’ means carriage of one or two copies of HLA-Cw6 but no copies of HLA-Cw1-B46, ‘Cw6 + Cw1-B46’ means carriage of one
HLA-Cw6 and one HLA-Cw1-B46 haplotype, ‘neither’ means carriage of neither a HLA-Cw6 nor a HLA-Cw1-B46 haplotype, and ‘missing’ means the
HLA-CB haplotypes are unknown because of typing failures. In this sample, HLA-B46 haplotypes always carry HLA-Cw1 (see Table 3).
bNumber of individuals
cMean and standard error for raw variable values are shown, but before analysis data were transformed to approximate normality using the optimal
Box–Cox power transformation (power of 0.8 for age at onset and 0.3 for TBSA).
dP-values for age at onset and TBSA are for one-way ANOVA, based on 10,000 random permutations of the response variable observations; P-values for
toenail and fingernail involvement and arthritis are for Fisher’s exact test on an unordered two-way contingency table. All tests excluded individuals
with a missing HLA-CB phenotype.
this has been confirmed in the Han Chinese (7). However,
considerable evidence indicates that HLA-Cw6 is not the
only psoriasis susceptibility allele in the MHC. Psoriatic
arthritis has also repeatedly been associated with HLA-B38
and HLA-B39 (splits of HLA-B16 ) (37–43) and with HLA-
B27, especially when axial involvement is present (39, 40,
42, 44). Moreover, we have recently shown that additional,
albeit less genetically robust, association signals are present
in the MHC class III region (35, 45). Together with the HLA-
Cw1-B46 association, which is the focus of this study, these
findings suggest that genetic heterogeneity is likely to be
present at PSORS1, with various effects on the phenotype.
Our interest in the HLA-Cw1-B46 haplotype stemmed from
several prior demonstrations of disease association in Asian
populations (9, 10, 12, 13, 15, 46). Taking advantage of
a collection of Thai psoriasis patients and normal controls
independent of those collected previously, we were able to
robustly confirm the association of psoriasis with HLA-Cw6,
HLA-Cw1, HLA-B46, and the HLA-Cw1-B46 haplotype in our
Thai sample (Table 1). In order to assess whether these asso-
ciations might be a result of allelic heterogeneity at HLA-C,
we tested for HLA-Cw1 -specific associations with psoriasis in
the Thai and Caucasian populations. In our Thai sample, hap-
lotypes carrying HLA-Cw1 but lacking HLA-B46 showed no
significant association with psoriasis (Table 2), but our sam-
ple lacks adequate power given the relatively low frequency
of this haplotype. However, similar findings, in a Japanese
study (11) where HLA-Cw1 not on HLA-B46 haplotypes
trended toward negative association with psoriasis (OR =
0.45, P = 0.068) and in a Thai study (9) where the strength
of association of HLA-B46 with psoriasis (OR = 4.23, P =
1.4 × 10−6) was much greater than that for HLA-Cw1 (OR =
1.70, P = 0.083), increase the likelihood that HLA-Cw1 is
not a direct determinant of psoriasis in East Asians.
In our Caucasian sample, which showed highly significant
evidence for association with HLA-Cw6, we found no evi-
dence for association with HLA-Cw1 despite >99% power
to detect an association of the strength observed in the Thai
population. No occurrences of the HLA-B46 allele were seen
for a large genotyped subset of our Caucasian sample, which
includes all HLA-Cw1 carriers, confirming the specificity of
HLA-Cw1-B46 for Asian populations. While two small studies
have reported association of HLA-Cw1 with psoriatic arthri-
tis (47, 48), this may reflect the fact that HLA-Cw1 is in
linkage disequilibrium with HLA-B27 in Caucasian popula-
tions. However, HLA-Cw1 was clearly unassociated with 493
psoriatic arthritis cases in our own much larger Caucasian
sample (P = 0.38), with an effect size nearly identical to
that seen for 1,549 purely cutaneous psoriasis cases in the
same sample (OR = 0.84 vs 0.85, respectively). One other
study of 50 pediatric Kuwaiti psoriatics and 120 controls
yielded a positive association with HLA-Cw1, but no asso-
ciation with HLA-Cw6 (49). Whether this divergent finding is
the result of small sample size, different ethnicity (predomi-
nantly Arab), very early onset (<12 years), or the presence of
arthritis (which was not reported) remains to be determined.
Overall, it appears highly unlikely that HLA-Cw1 itself is a
psoriasis risk determinant in either Thais or Caucasians. Hence
another MHC locus, perhaps HLA-B46 itself, is driving the
observed associations with the HLA-Cw1-B46 haplotype.
Consistent with data presented by others, we noted that
HLA-Cw6 appears to be more strongly associated with
psoriasis than is HLA-Cw1-B46 in the Thai population. While
the 95% CI for the two ORs estimated from our sample
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overlapped (Table 1), the greater strength of the HLA-Cw6
association could be statistically established after combining
our study with the only other relevant Thai study with allele-
based HLA genotyping (10). In addition, three out of four of
the older serological studies (11–13) corroborate the greater
risk of disease imparted by HLA-Cw6 compared with HLA-
Cw1-B46 in Asian populations.
To our knowledge there is no evidence for an association
between guttate psoriasis and the HLA-Cw1-B46 haplotype, in
contrast to its strong association with HLA-Cw6 (50). It is also
notable that the HLA-Cw1-B46 haplotype has been associated
with other autoimmune diseases, including myasthenia gravis
and Graves disease (51), whereas HLA-Cw6 has not. More-
over, Romphruk et al. reported that HLA-Cw1-B46 is equally
associated with early and late-onset disease in Thai psoriatics,
whereas HLA-Cw6 is more strongly associated with early-
onset disease (46). Taken together with the aforementioned
difference in strength of association, these findings suggested
that the psoriasis susceptibility determinants carried on these
two haplotypes are different. We tested this hypothesis in two
ways: by performing a sequence analysis of the two haplo-
types, and by comparing the phenotypes of known carriers of
each haplotype.
Detailed sequence comparison with eight non-risk haplo-
types (Figure 1 and Table 3) found no single variants unique
to the HLA-Cw1-B46 and HLA-Cw6 risk haplotypes within
potential IBD regions of homology in the PSORS1 candidate
interval. Although two-way and three-way combinations of
variants unique to these two risk haplotypes do exist, they are
confined to a 55 kb region that contains no known genes and
that has equivalent similarity with two non-risk haplotypes
(Figure 2). Nevertheless, based on sequence analysis alone,
we cannot completely exclude the possibility that this region
contains a variant that is IBD within a regulatory element or
a novel expressed gene.
Phenotypic analysis provided additional support for the
hypothesis of genetic heterogeneity, although its conclusions
must be tempered by sample size considerations. We found
that Thai psoriatics carrying HLA-Cw1-B46 have a later age
at onset and greater nail involvement than do carriers of the
HLA-Cw6 risk haplotype (Table 4). However, it is impor-
tant to note that age at onset correlates with the presence
or absence of HLA-Cw6 but not of HLA-Cw1-B46, and like-
lihood of nail involvement with the presence or absence of
HLA-Cw1-B46 but not of HLA-Cw6. Together, the weight
of evidence from these sequencing and phenotype compar-
isons strongly favors the hypothesis that the HLA-Cw1-B46
and HLA-Cw6 risk haplotypes do not derive from a common
ancestral risk chromosome.
Given these findings in support of genetic heterogeneity,
the evolutionary history of HLA-B46 is of interest. In 1992,
Parham and colleagues dissected a complicated serological
determinant known as Cw1x3 antigen (also called Cw11,
CwB, Cx46, Cw1+3, C-Bangkok, and CSH1). In doing so,
they showed that the HLA-B46 allele is the result of an
unusual gene conversion event in which a 31-bp segment of
HLA-Cw1 encoding residues 66–76 of the α1 helix replaced
the corresponding sequences of the HLA-B62 allele (52). Hap-
lotypes containing HLA-B62 and HLA-Cw1 are not uncom-
mon in Asian populations (53), supporting the notion of a
gene conversion event rather than recombination. HLA-B62
has a worldwide distribution, whereas HLA-B46 is specific
for Asian populations, showing that HLA-B62 is the ancestral
allele and that the gene conversion occurred in an individual
of Asian descent. HLA-B46 is a common allele in Asian pop-
ulations, suggesting that this event was followed by marked
expansion in the population. Whether this expansion reflects
positive selection for pathogen resistance, analogous to the
postulated selection for HLA-Cw6 in resistance to Strepto-
coccal pneumonia (54), is unknown.
The 11 amino acids transferred from HLA-Cw1 to HLA-B62
by gene conversion differ from the corresponding residues of
HLA-Cw6 only at amino acid residue 73 (threonine in HLA-
Cw1 vs alanine in HLA-Cw6 ). Because we have shown here
that HLA-Cw1 is not disease-associated, on the (unproven)
hypothesis that this specific segment of HLA-C confers
disease susceptibility, we could infer that alanine residue
73 is unlikely to be of critical importance, as previously
suggested (55). However, there are many other possible
explanations for the observed HLA-B46 association. HLA-
B and HLA-C are very similar to each other, reflecting a
relatively recent gene duplication (56). As MHC class I genes,
both HLA-B and HLA-C are involved in the presentation
of peptides to CD8+ T cells, whose emigration into the
epidermis appears to be necessary for the development of
epidermal hyperplastic response (57). One possibility would
be that the two alleles could be presenting different antigens.
Alternatively, another nearby gene in the MHC class III region
could be the causative agent on the HLA-Cw1-B46 haplotype.
Several of these genes are strong functional candidates. For
instance, MICA and MICB are nonclassical MHC genes that
participate in the regulation of CD8+ T cells and natural
killer (NK) cells (58), and the tumor necrosis factor and
lymphotoxin genes encode proteins whose blockade is highly
therapeutically effective (59). While our earlier studies of
recombinant ancestral haplotypes argue strongly against a
primary role for MHC class III genes as the drivers of the
HLA-Cw6 association signal (6, 60), no comparable mapping
studies exist as yet for the HLA-Cw1-B46 disease association
in Asians. Thus, at this stage it is premature to speculate that
the genetic heterogeneity suggested by our data must involve
HLA-B46 itself, although it is certainly possible.
In conclusion, we have presented several lines of evidence
for a distinct PSORS1 locus in the Thai population. Future
genetic studies of this allele in Asian populations should
focus on increasing sample size and high-density genotyping
of HLA-B, its flanking sequences, and the MHC class III
region.
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